HUTCHMED's sovleplenib gets FDA orphan drug designation

For primary ITP, sovleplenib is eligible for U.S. orphan-drug incentives, including market exclusivity, only if FDA approves it for the indication.

Rhea-AI Filing Summary

HUTCHMED (China) Limited announced that the U.S. FDA granted orphan drug designation to sovleplenib for treatment of primary immune thrombocytopenia (ITP), an autoimmune disorder that can increase bleeding risk. If FDA approves sovleplenib for this indication, it would be eligible for 7 years of U.S. market exclusivity, tax credits for qualified clinical trials, Prescription Drug User Fee Act fee waivers and specialized FDA guidance during clinical development.

In China, New Drug Applications for sovleplenib in primary ITP and warm antibody autoimmune hemolytic anemia are under regulatory review by the National Medical Products Administration. HUTCHMED says the applications are supported by positive data from the pivotal ESLIM-01 and ESLIM-02 trials, respectively, and that it retains all worldwide rights to sovleplenib.

Key Figures

Potential U.S. market exclusivity: 7 years U.S. orphan-designation population threshold: Fewer than 200,000 people Primary ITP incidence: 3.3 per 100,000 adults per year +3 more

6 metrics

Potential U.S. market exclusivity 7 years Eligible upon FDA approval for the designated indication

U.S. orphan-designation population threshold Fewer than 200,000 people FDA orphan drug designation program

Primary ITP incidence 3.3 per 100,000 adults per year Adults

Primary ITP prevalence 9.5 per 100,000 adults Adults

Estimated primary ITP patients Approximately 110,000 patients China

Estimated chronic ITP patients As many as 145,000 patients Major pharmaceutical markets excluding China

Key Terms

Orphan Drug Designation, spleen tyrosine kinase (Syk) inhibitor, New Drug Applications, primary immune thrombocytopenia

4 terms

Orphan Drug Designation regulatory

"granted Orphan Drug Designation to sovleplenib"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

spleen tyrosine kinase (Syk) inhibitor technical

"selective, oral spleen tyrosine kinase (Syk) inhibitor"

New Drug Applications regulatory

"New Drug Applications (NDAs) for sovleplenib"

New drug applications are formal requests submitted to a medicine regulator asking permission to market a new prescription drug after clinical testing. Think of it as a company presenting proof, like a recipe and test results, to a safety inspector to show the product works and is safe; approval unlocks the ability to sell the drug, while rejection or delay can sharply change a company’s potential revenue and stock value.

primary immune thrombocytopenia medical

"treatment of primary immune thrombocytopenia"

An autoimmune disorder in which the body's immune system attacks and destroys its own platelets and often interferes with platelet production in the bone marrow, causing a sustained low platelet count (thrombocytopenia) and increased bleeding risk. It is called “primary” when no other underlying condition (such as infection, another autoimmune disease, medication effect, or malignancy) explains the platelet loss; diagnosing it typically requires ruling out those secondary causes. Clinical management and severity vary with platelet count and bleeding symptoms, but the core mechanism is immune‑mediated platelet destruction and impaired platelet production.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What FDA designation did HCM's sovleplenib receive?

The U.S. FDA granted sovleplenib orphan drug designation for primary immune thrombocytopenia (ITP). The designation is for the treatment of this indication.

What incentives could HCM's sovleplenib receive with orphan drug designation?

If approved by the FDA for the designated indication, sovleplenib would be eligible for 7 years of U.S. market exclusivity, tax credits for qualified clinical trials, user fee waivers under the Prescription Drug User Fee Act and specialized FDA guidance during clinical development.

Where are HCM's sovleplenib applications under review?

In China, New Drug Applications for primary ITP and warm antibody autoimmune hemolytic anemia are under regulatory review by the National Medical Products Administration. The applications are supported by positive data from the pivotal ESLIM-01 and ESLIM-02 trials, respectively.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/29/2026 - 06:08 AM EDT Accepted by SEC EDGAR 10/29/2026 - 06:08 AM EDT Learn about SEC filing dates

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 6-K

​

​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

​

For the Month of October 2026

​

Commission File Number: 001-37710

​

​

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

​

​

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

​

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F  ⌧             Form 40-F  ◻

​

​

​

​

​

HUTCHMED (CHINA) LIMITED

​

Form 6-K

​

EXHIBIT INDEX

​

Exhibit No.	​ ​ ​	Description
​	​	​
Exhibit 99.1	​	Press release relating to HUTCHMED announces sovleplenib granted US FDA orphan drug designation for primary immune thrombocytopenia ​
​	​	​
​	​	​

2

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​	HUTCHMED (CHINA) LIMITED
​	​	​
​	​	​
​	By:	/s/ Johnny Cheng
​	Name:	Johnny Cheng
​	Title:	Chief Financial Officer

​

​

Date: October 29, 2026

3

Exhibit 99.1

​

​

Press Release

​

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia —

— Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoimmune condition —

— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval — 

Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 29, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the US Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia (“ITP”), an autoimmune disorder that can lead to increased risk of bleeding. Sovleplenib is a novel, selective, oral spleen tyrosine kinase (“Syk”) inhibitor.

​

The FDA’s Orphan Drug Designation program provides orphan status to drugs and biologics intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or conditions that affect fewer than 200,000 people in the United States. If approved by the FDA for the designated indication, drugs with Orphan Drug Designation are eligible for 7 years of US market exclusivity upon approval, tax credits for qualified clinical trials, user fee waivers under the Prescription Drug User Fee Act, and specialized regulatory guidance from the FDA during clinical development.

​

In China, New Drug Applications (“NDAs”) for sovleplenib in primary ITP and warm antibody autoimmune hemolytic anemia are currently under regulatory review by the National Medical Products Administration (NMPA), supported by positive data from the pivotal ESLIM-01 and ESLIM-02 trials in China, respectively.

​

About ITP

ITP is an autoimmune disorder characterized by immunologic destruction of platelets and decreased platelet production. Patients with ITP are at increased risk of excessive bleeding and bruising.¹ ITP is also associated with fatigue (reported in up to 39% of adults with ITP) and impaired quality of life.^2,3,4,5,6 The incidence of primary ITP in adults is 3.3/100,000 adults per year with a prevalence of 9.5 per 100,000 adults.⁷ Based on this prevalence rate, approximately 110,000 patients are estimated to be living with primary ITP in China, in addition to 56,000 patients in the US, Germany, France, Italy, Spain, UK, and Japan. It has been estimated that as many as 145,000 patients are living with chronic ITP in major pharmaceutical markets excluding China.⁸

​

Adult ITP is a heterogeneous disease that can persist for years, even with best available care, and treatments are infrequently curative. Despite availability of several treatments with differing mechanisms of action, chronicity of disease continues to be a problem. Many patients develop resistance to treatment and thereby are prone to relapse.⁹ Thus, there remains a significant population of patients who have limited sensitivity to currently available agents and are in need of new treatments.

​

As platelet destruction in ITP is mediated by Syk-dependent phagocytosis of FcγR-bound platelets, Syk inhibition represents a promising approach to management of ITP.¹⁰

​

About Sovleplenib

Sovleplenib is a novel, selective inhibitor of Syk for once daily oral administration. Syk is a major component in B-cell receptor and FcR signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders.

​

HUTCHMED currently retains all rights to sovleplenib worldwide. 

​

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

​

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of sovleplenib, the further clinical development for sovleplenib, its expectations as to whether any studies on sovleplenib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the timing and outcome of clinical studies and the sufficiency of clinical data to support NDA approval of sovleplenib for the treatment of patients with ITP or other indications in China or other jurisdictions, unexpected adverse events or safety issues; the ability of sovleplenib to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of sovleplenib for a targeted indication; the sufficiency of funding; HUTCHMED’s ability to successfully develop and commercialize sovleplenib. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

​

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

​

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
​ ​Ben Atwell / Tim Stamper	​ ​+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

_____________________________________

REFERENCES

¹ Zufferey A, et al. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J. Clin. Med. 2017, 6(2), 16.

² McMillan R, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008 Feb;83(2):150-4.

³ Snyder CF, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin. 2008 Oct;24(10):2767-76.

⁴ Doobaree IU, et al. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol. 2016 Oct;97(4):321-30.

⁵ Sarpatwari A, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica. 2010 Jul;95(7):1167-75.

⁶ Sarpatwari A, et al. Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP). Br J Haematol. 2010 Oct;151(2):189-91.

⁷ Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017 May 25;129(21):2829-2835.

⁸ Clarivate Landscape & Forecast for Immune Thrombocytopenic Purpura, 2018.

⁹ Provan D, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817.

¹⁰ Crowley MT, et al. A critical role for Syk in signal transduction and phagocytosis mediated by Fcγ receptors on macrophages. J. Exp. Med. 186(7), 1027–1039 (1997).

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 28.9 KB